(+) Achillion: Oppenheimer Healthcare Conference (Achillion) - Dec 12, 2013 - "Very rapid reduction in HCV RNA demonstrated with sovaprevir + ACH-3102 + RBV in GT1: All GT1 subjects achieved vRVR, defined as an HCV RNA <25 IU/mL by week 2"; "Potent anti-viral activity demonstrated against GT1b: 100% RVR in the 200mg and 400mg dose groups; All subjects achieved HCV RNA <10 IU/ml at week 4; Subject with the Y93H mutation at baseline, which is highly resistant to first-generation NS5A inhibitors, achieved RVR"; "RVR was achieved in 79% of GT1 subjects overall"
P2 data • Hepatitis C Virus
|